|
Aurobindo Pharma Limited has
registered a Total income of Rs.5547 million
(Rs. 4169.7 million), EBITDA of Rs.1048 million
(Rs.661.8million) and PAT of Rs.601 million
(Rs.261.9 million) for the quarter ended
December 31, 2006. |
|
During the quarter the Total
Income, EBITDA and PAT have shown a growth of
33%, 58% and 130% respectively as compared to
the corresponding quarter of previous year. The
operating margin (EBITDA) and PAT have risen to
19% (16%) and 11% (6%) respectively. |
|
Aurobindo’s continued thrust into
regulated markets and formulation business has
contributed to the company’s improved product
mix quarter by quarter. |
|
The formulations sales have grown
by 70% and now constitute 30% total sales.
Aurobindo has been successful in capturing
significant market share for its products in
USA. By Q4 it would have completed most of the
launches for approved products. |
|
Export sales have grown by 30%
and constitute 58% (57%) of total sales. The
exports have shown significant improvement
across all markets. The contribution of India,
Americas, Europe & ROW to the total exports now
stand at 42%, 17%, 18% & 23% respectively. |
|
During the quarter Aurobindo has
acquired Pharmacin international B.V.,
Netherlands, a profit making generic company
extending its European presence. |
|
ISO 14001 Award
Aurobindo’s manufacturing unit has received the
ISO 14001 certification. |
|
Asia Star packaging award
Aurobindo during the quarter has won Asia star
award for its unique functional packaging of
Citalopram for US market. |
|
Further ramping up of filings in
Q3 FY07
During the quarter Aurobindo has filed 6ANDAs
and 11DMFs for US and has filed 18 formulation
filings in other markets. The total number of
formulation filings now stands at 199 |
|
Aurobindo has filed additional 13
patents during the quarter and the cumulative
filings stand at 229 as of December 31, 2006. |
|
Snapshot of filings : |
|
|
Q3 FY07
|
Cumulative as on
Dec 31, 2006 |
ANDAs/USA
|
6 |
75 |
|
DMFs/USA |
11 |
104 |
|
Formulation dossiers in
Europe, South Africa , Canada & WHO |
18 |
124
|
|
API dossiers in Europe &
Canada & other countries |
47 |
246 |
|
Patents |
13 |
229 |
|
|
DMFs /ANDAs /formulation
dossiers filed across globe. |
1508 |
|
|
Financial Snapshot: (Quarter 3 FY
07) |
|
Rs. Mio |
|
|
Q3 FY07
|
% Growth |
Total
income
|
5547 |
33 |
|
EBIDTA |
1048 |
58 |
|
PBT |
688 |
89 |
|
PAT |
601 |
130 |
|
| |
|
Q3 FY 06 |
|
EBIDTA % |
19 |
16 |
|
PAT% |
11 |
6 |
|
|
Financial Snap shot Cumulative
Dec 31, 2006 |
| |
|
Rs. Mio |
|
|
9MonthlyFY07
|
% Growth |
Total
income
|
15171 |
48 |
|
EBIDTA |
2836 |
133 |
|
PBT |
1800 |
347 |
|
PAT |
1510 |
374 |
|
| |
|
Cumulative 9M FY 06 |
|
EBIDTA % |
19 |
12 |
|
PAT% |
10 |
3 |
|
|
Sales Snapshot: |
|
Growth across business
segments.
Rs. Mio |
|
Markets |
9M-07
|
9M-06
|
Gr |
Markets |
9M-07
|
9M-06
|
Gr |
|
India |
6100 |
4660 |
31 |
India |
6100 |
4660 |
31 |
|
Americas |
2460 |
1377 |
79 |
Americas |
2460 |
1377 |
79 |
|
Europe |
2280 |
1031 |
121 |
Europe |
2280 |
1031 |
121 |
|
ROW |
3620 |
3020 |
20 |
ROW |
3620 |
3020 |
20 |
|
|
Product Mix |
Growth (Q3 O Q3) % |
% to Total |
|
APIs |
17 |
70 |
|
Formulations |
70 |
30 |
|
|
Q3FY07 Vs Q3FY06: All-round
growth |
 |
 |
|
|
Sequential Q after Q Growth
in Sales |
 |
|
|
Robust Q after Q Growth in
EBITDA |
 |
|
|
Q after Q improved
Formulation Sales |
 |
|
|
About Aurobindo Pharma Limited: |
|
Aurobindo Pharma Limited
(www.aurobindo.com), headquartered at Hyderabad,
India, manufactures generic pharmaceuticals and
active pharmaceutical ingredients. The company
has received approvals for most of the targeted
API and formulation facilities from leading
regulatory agencies such as US FDA, UK MHRA,
WHO, Health Canada, MCC South Africa. The
company’s robust product portfolio is spread
over 6 major therapeutic/product areas
encompassing Antibiotics, Anti-Retrovirals, CVS,
CNS, Gastroenterologicals, and Anti-Allergics.
The formulation portfolio is
built on six technology platforms such as
immediate release generics, SR/CR generics,
orally disintegrating/mouth dissolving generics,
combination products, sterile/lyophilized
generics and liquids/dry syrups.
Aurobindo has filed over 100 DMFs
and 75 ANDAs for the USA market in addition to
filings in other countries. The pace of filings
is matched by rapid product approvals from
various markets. Till date Aurobindo received 37
ANDA approvals (both final and tentative) from
US FDA.
Aurobindo operates in over 100
countries and markets over 180 APIs and 250
formulations. |
For further information,
please contact:
Investor Relations
Aurobindo Pharma Limited
Plot # 2, Maitri Vihar | Ameerpet
Hyderabad - 500 038 |India
Phone (Board): +91 40 6672 5000
Email : ir@aurobindo.com |
|
|
|
|
PRESS
ROOM
